RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Recruiting now
Conditions studied: Sickle Cell Disease, Thalassemia, Hemolytic; Anemia, Hereditary, Due to Enzyme Disorder, Anemia Due to Membrane Defect, CDA, Sideroblastic Anemia, Constitutional Aplastic Anemia, Iron Metabolism Disorders, Hereditary Anemia
In brief
Rare Anaemia Disorders (RADs) is a group of rare diseases characterized for presenting anaemia as the main clinical manifestation. Different medical entities classified as RADs by ORPHA classification are most of them chronic life threating disorders with many unmet needs for their proper clinical management creating an impact on European health systems. RADs present diagnostic challenges and their appropriate management requires from specialised multidisciplinary teams in Centers of expertise. Although there are some examples of well-established national registries on RADs in EU, the lack of recommendations for Rare disease registries implementation and the lack of standards for interoperability has led to the fragmentation or unavailability of data on prevalence, survival, main clinical manifestations or treatments in most of the European countries.
Key facts
- Study ID
- NCT06213402
- Run by
- Hospital Universitari Vall d'Hebron Research Institute
- People needed
- 32564
- Starts
- 2021-11-30
- Expected to finish
- 2036-11-01
- Last updated by the study team
- 2024-01-19
Who can join
Age: any, up to 100. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients must meet all of the following criteria to be included in the RADeep Registry
- Age from 0-100, both female and male
- Diagnosed as RADs (SCD, THAL, PKD, and other RADs THAL according to ORPHANET classification)
- Able and willing to provide written informed consent (patient or legal representative for minors)
You may not qualify if…
- Patient or legal representative for minors unwilling or unable to give consent
- Patients diagnosed with SCD or THAL (alpha-thalassaemia and beta-thalassaemia) traits or trait conditions for other recessive RADs
Where it is running
- Vall d'hebron Research Institute - Vall d'Hebron Research Institute - University Hospital Vall d'Hebrón (VHIR/HUVH) — Barcelona, Catalonia, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.